Literature DB >> 3923921

In vitro and in vivo activities of formycin B against Trypanosoma cruzi.

R E McCabe, J S Remington, F G Araujo.   

Abstract

The inosine analog formycin B was examined for in vitro and in vivo activities against Trypanosoma cruzi. concentration of formycin B as low as 0.1 microgram/ml markedly inhibited intracellular multiplication of T. cruzi strains both in macrophages and in L929 cells. Mice infected with 10(5) blood form trypomastigotes of the highly virulent strain Y of T. cruzi were completely protected against death by treatment with 11.8 or 5.9 mg of formycin B per kg administered intraperitoneally each day for 19 days. Four different strains of T. cruzi were used, and each was susceptible to formycin B administered either intraperitoneally or orally. Parasitological cure, however, was not achieved with any of the treatments used, including prolonged treatment for up to 10 weeks. Formycin B has a remarkable capacity for inhibiting the in vitro intracellular replication of T. cruzi and protecting mice against death due to the acute infection with the organism. It does not appear, however, to be able to completely eliminate T. cruzi from infected mice.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3923921      PMCID: PMC180081          DOI: 10.1128/AAC.27.4.491

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Western Hemisphere.

Authors:  Z Brener
Journal:  Pharmacol Ther       Date:  1979       Impact factor: 12.310

2.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.

Authors:  Z BRENER
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1962 Nov-Dec       Impact factor: 1.846

3.  (COMPARATIVE STUDIES OF DIFFERENT STRAINS OF TRYPANOSOMA CRUZI.)

Authors:  Z BRENER
Journal:  Ann Trop Med Parasitol       Date:  1965-03

4.  Biological action of inosine analogs in Leishmania and Trypanosoma spp.

Authors:  J J Marr; R L Berens; N K Cohn; D J Nelson; R S Klein
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

5.  The metabolism and cytotoxic effects of Formycin B in Trypanosoma cruzi.

Authors:  P Rainey; C E Garrett; D V Santi
Journal:  Biochem Pharmacol       Date:  1983-02-15       Impact factor: 5.858

6.  In vitro susceptibility of antimony-resistant Leishmania to alternative drugs.

Authors:  J D Berman
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

Review 7.  Immunobiology of Trypanosoma cruzi infection and Chagas's disease.

Authors:  L Hudson
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

8.  Phosphorylation and anti-leishmanial activity of formycin B.

Authors:  D A Carson; K P Chang
Journal:  Biochem Biophys Res Commun       Date:  1981-06-16       Impact factor: 3.575

9.  An in vitro model for investigation of chemotherapeutic agents in leishmaniasis.

Authors:  J D Berman; D J Wyler
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

10.  Ketoconazole protects against infection with Trypanosoma cruzi in a murine model.

Authors:  R E McCabe; F G Araujo; J S Remington
Journal:  Am J Trop Med Hyg       Date:  1983-09       Impact factor: 2.345

View more
  3 in total

1.  Biological activity of analogs of guanine and guanosine against American Trypanosoma and Leishmania spp.

Authors:  J L Avila; T Rojas; A Avila; M A Polegre; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

2.  Novobiocin antagonism of amastigotes of Trypanosoma cruzi growing in cell-free medium.

Authors:  P G Pate; J S Wolfson; G L McHugh; S C Pan; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

3.  Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box.

Authors:  Juan Cantizani; Pablo Gamallo; Ignacio Cotillo; Raquel Alvarez-Velilla; Julio Martin
Journal:  PLoS Negl Trop Dis       Date:  2021-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.